Pharmaceuticals company Lincoln Pharmaceuticals announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: For the Quarter ended in March 2025, company reported a standalone net profit of Rs 11.62 crore. EBITDA of Rs 19.84 crore and Total Income from operations at Rs 161.30 crore. EPS for Q4FY25 was at Rs 5.78 per share. FY25 Financial Highlights: Lincoln Pharmaceuticals reported a standalone net profit of Rs 82.44 crore for the FY25 ended March 2025 as against net profit of Rs 93.37 crore FY24. Total Income from operations for the FY25 was reported at Rs 645.71 crore over previous fiscal's same period revenue from operations of Rs 614.97 crore. Company reported EBITDA of Rs 123.97 in FY25 as compared to Rs 134.33 crore EBITDA in the corresponding period last year. EPS for FY25 was at Rs 41.1 per share. Company has recommended a dividend of 18 %, Rs 1.80 per share on the face value of Rs 10 per share for the FY 2024-25. Commenting on the Q4 and FY25 performance, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said, "Lincoln Pharmaceuticals has delivered consistent profit growth from FY13 through FY24 - a testament to our sound business fundamentals and execution capabilities. Company remain committed to net debt-free and continue to leverage strategic product launches in both domestic and international markets to strengthen our market presence. We are committed to significantly improve our growth going forward. With a clear focus on operational excellence and geographic expansion, we are well-positioned to achieve our Rs 750 crore revenue target by FY26." Result PDF